Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers

BMC Pharmacology and Toxicology

Volumn 18, Issue 1, 2017, Pages

  Chandorkar, Gurudatt ^a   Zhan, Qiao ^a   Donovan, Julie ^a   Rege, Shruta ^a   Patino, Hernando ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clostridium difficile; Clostridium difficile infection; Clostridium difficile associated diarrhea; Surotomycin

Indexed keywords

AMINOTRANSFERASE; PLACEBO; SUROTOMYCIN; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

ADULT; ADVERSE DRUG REACTION; AGED; ANXIETY; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFECTION; INFESTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; MORNING DOSAGE; MUSCULOSKELETAL DISEASE; NORMAL HUMAN; OROPHARYNX PAIN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOLUNTEER; ADOLESCENT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEALTHY VOLUNTEERS; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; YOUNG ADULT;

EID: 85016149305     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/s40360-017-0123-z     Document Type: Article

References (17)

1. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18 Suppl 6:5-12.
2. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1-14.
3. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. U.S. Department of Health and Human Services. 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 26 Oct 2016.
4. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309-18.
5. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30:57-66.
6. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12 Suppl 6:2-18.
7. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55 Suppl 2:S65-70.
8. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-90.
9. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-7.
10. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007;102:2781-8.
11. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345-54.
12. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother. 2008;52:2403-6.
13. Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol. 2003;24:644-9.
14. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother. 2012;56:5023-30.
15. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother. 2012;56:1613-5.
16. Snydman DR, Jacobus NV, McDermott LA. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother. 2012;56:3448-52.
17. Rayner CK, Horowitz M. Physiology of the ageing gut. Curr Opin Clin Nutr Metab Care. 2013;16:33-8.